Adaptive Biotechnologies Corporation · NASDAQ:ADPT
Adaptive Biotechnologies — Q3 2020 Earnings Presentation
14 slides from Adaptive Biotechnologies's earnings presentation, Nov 10, 2020
Slide 1: Third Quarter 2020 Earnings Conference Call
Third Quarter 2020 Earnings Conference Call November 10, 2020
Slide 2: Safe harbor
Safe harbor This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements co
Slide 3: Q3 2020 Key Highlights
Q3 2020 Key Highlights Q3 revenues of $26.3M (+25% vs P/Q and +1% vs P/Y) immunoSEQ T-MAP COVID to be used in a subset of patients from clinical trials of two top tier vaccine developers clonoSEQ test volume grew 28% vs P/Q and 58% vs P/Y; Launched clonoSEQ for patients in CLL Q3’20 Preparing for la
Slide 4: Translating the Genetics of Immune System into Clinical Products
Translating the Genetics of Immune System into Clinical Products One immune medicine platform Synergistic data interplay Immune driven products Life Science Clinical Drug Clinical Research Diagnostics Discovery Diagnostics COMMERCIAL COMMERCIAL IMMUNO- MRD SEQUENCING MONITORING Immune Receptor Produ
Slide 5: Outperformed Leading Antibody Tests in Real-World Studies
Outperformed Leading Antibody Tests in Real-World Studies New Study Previously Published Study Sensitivity Sensitivity 97% 94% 77% 90% 87% Positive by Positive by IgG Positive by Positive by IgG Positive by IgG T-Detect Assay1 only T-Detect COVID and IgM (Roche) only (Labcorp) • Population: 2,200+ p
Slide 6: TruAB Discovery, Identifying Best-In-Class SARS-CoV-2 Neutralizing Antibodies
TruAB Discovery, Identifying Best-In-Class SARS-CoV-2 Neutralizing Antibodies COVID-19 patients: 300+ recovered plus 35+ symptomatic / acute infection 333,000+Abs 1,630 Abs produced & assessed 185 Abs strongly bind spike 25 Abs strong inhibition Focus on top 2 Abs with strong live virus neutralizati
Slide 7: LSR: Driving Adoption on RUO Kit and Traction on T-MAP COVID
LSR: Driving Adoption on RUO Kit and Traction on T-MAP COVID Recovery observed, but still not at pre-COVID levels T-MAP COVID, measuring T-cell response in vaccine trials Uptake observed during Q3 2020 as more U.S labs are Getting traction among vaccine developers opened although partially staffed −
Slide 8: clonoSEQ: Focus on Clinical Adoption
clonoSEQ: Focus on Clinical Adoption Strong clonoSEQ volume trajectory clonoSEQ growth drivers Q3 test volume +58% vs P/Y; +28% vs P/Q Broad CLL promotional and medical education plan to reach Used in all 30 NCCN centers and over 14,000 unique patients target audiences − Over 685 new HCPs were added
Slide 9: First T-cell Based Test for COVID-19 and First T-Detect Indication
First T-cell Based Test for COVID-19 and First T-Detect Indication Value Proposition Go-to-Market Approach Confirm past infection: better sensitivity vs serology in Primary targets: active & concerned consumers (self-pay); real-world setting concierge medicine; employers; public health agencies Prod
Slide 10: Progressing on Lyme while Confirming New Signal
Progressing on Lyme while Confirming New Signal LYME: significant improvement vs gold standard T-Detect: Other Indications ImmuneSENSE study: looking to enroll 990 patients Confirmed 3rd T-Detect signal for Crohn’s disease − ~800 to be enrolled by YE 2020 Other indications continue through developme
Slide 11: Drug Discovery: Progress Continues in Both TCR and BCR Efforts
Drug Discovery: Progress Continues in Both TCR and BCR Efforts Characterize TCRs against cancer antigens Characterize antibody-secreting BCRs for SARs-CoV-2 1st shared product: Genentech remains on track for an Identified 2 highly potent neutralizing antibodies against IND submission by Q1 2021 SARS
Slide 12: Q3 2020 Financial Highlights
Q3 2020 Financial Highlights Revenues & Volumes Operating Expenses1 Revenues ($’000) ($’000) $62,920 +44% $26,058 $26,299 +1% Sequencing rev $12,079 +42% Development rev $11,683 $11,276 -3% $43,683 $14,474 +59% $14,375 $15,023 +5% $8,477 Q3 2019 Q3 2020 $9,099 Sequencing Volume +48% $30,314 $20,506
Slide 13: Key Catalysts in the Next 12-18 Months
Key Catalysts in the Next 12-18 Months Upcoming Milestones Further immunoSEQ T-MAP COVID integration in SARS-CoV-2 vaccine trials in 2021 Life Science Research Continue to penetrate core labs and partner with CROs to use immunoSEQ RUO kit clonoSEQ ALL in blood filing with FDA; commercialize in 2021
Slide 14: Slide 14
Adaptive Biotechnologies — Q3 2020 Earnings Presentation on 6ix